Understand the source comparison
SS-LUP-332 Clinical Trials 2026: Drug Class Comparison
Below is a comparison of SS-LUP-332 with established metabolic drug classes based on mechanism, clinical endpoints, and adverse event profiles. This table synthesizes data from phase II trials, FDA-approved drug labels, and peer-reviewed meta-analyses publishe
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Below is a comparison of SS-LUP-332 with established metabolic drug classes based on mechanism, clinical endpoints, and adverse event profiles. This table synthesizes data from phase II trials, FDA-approved drug labels, and peer-reviewed meta-analyses published through mid-2026.
- SS-LUP-332
- AMPK activation + mitochondrial biogenesis
- 6.8% (12-week interim)
- −0.7% (projected)
- <5% nausea, zero discontinuations
- No QT prolongation or arrhythmia in phase I
- Novel mechanism with metabolic flexibility benefits; phase II data needed to assess durability vs GLP-1 agonists
- Semaglutide 2.4mg
- GLP-1 receptor agonist (appetite suppression, delayed gastric emptying)
- 12–15%
- −1.5 to −2.0%
- 30–44% nausea, 15–18% discontinuation
- CVOT positive (MACE reduction 20%)
- Gold standard for weight loss efficacy but limited by GI tolerability; metabolic benefits reverse rapidly after discontinuation
- Tirzepatide 15mg
- Dual GIP/GLP-1 agonist
- 15–20%
- −2.0 to −2.5%
- 25–35% nausea, 12–16% discontinuation
- CVOT ongoing (expected 2027)
- Highest efficacy for weight and glycemic control; same tolerability and durability limitations as semaglutide
- Metformin
- AMPK activation (hepatic glucose suppression)
- 2–3%
- −0.5 to −1.0%
- 20–30% diarrhea, usually transient
- Neutral CV outcomes
- First-line therapy for T2DM; modest weight effect; SS-LUP-332 shares AMPK mechanism but adds mitochondrial component
- SGLT2 Inhibitors
- Renal glucose excretion
- 2–4%
- −0.5 to −0.8%
- 10–15% genital infections
- CVOT positive (HF hospitalization reduction)
- Cardiovascular and renal benefits independent of weight loss; limited obesity efficacy as monotherapy
- The bottom line: SS-LUP-332 occupies a mechanistic niche that no approved drug currently fills—metabolic rate enhancement without appetite suppression, thyroid stimulation, or sympathomimetic effects. If phase II confirms the interim metabolic flexibility improvements, the compound could serve as combination therapy for patients on GLP-1 agonists who plateau or as monotherapy for those intolerant to incretin-based treatments. The <5% gastrointestinal adverse event rate represents a meaningful tolerability advantage, though absolute weight loss efficacy appears lower than tirzepatide or high-dose semaglutide.